180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced two new appointments to its board of directors: Pamela Marrone, PhD, and Frank Knuettel II, MBA. Marrone has garnered vast experience over her 30-year career as a corporate leader and CEO. She has led the charge in building, innovating and commercializing a range of companies, including launching products and setting up distribution deals in more than 40 countries. In addition, she has been instrumental in breaking new ground on regulatory approvals and building award-winning, patented products. Knuettel has more than 25 years of management experience in venture, PE-backed and public companies; his expertise includes growing businesses, debt and equity financings, offerings and restructurings, M&A and leadership in and management of highly dynamic, swiftly growing companies. He has served as CEO, CFO and board member in numerous organizations; he also has experience managing mergers and acquisitions. “We are pleased to welcome both Pam and Frank to our board,” said 180 Life Sciences CEO Dr. James Woody in the press release. “I expect that their unique skill sets will be highly complementary to our other two recent additions to our board. I look forward to working with both Pam and Frank, along with our entire board of directors, focusing on building sustainable shareholder value.”
To view the full press release, visit https://ibn.fm/wSOnc
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. 180 Life Sciences’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.